Skip to main content
Caplight Logo









DegenRx B.V.

DegenRx B.V.

Private
TilburgHealthcare & Life Scienceshttps://degenrx.com

Last Round

Grant

Jun 4, 2019

Company Overview

DegenRx B.V. is a biotechnology company developing AAV-mediated gene therapy for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyAAVadeno-associated-viral vectorsneurodegenerative diseaseblood-brain barriertherapeutic antibodiesbiotech startupCNS diseasesdrug discoverybiologicspre-clinical researchgenetic medicinebrain deliveryvector biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DegenRx B.V. Comparables

Compare DegenRx B.V. with similar companies based on industry and business-model similarity.

DegenRx B.V. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AviadoBio
84%
Klogene Therapeutics, Inc.
83%
Capsida Biotherapeutics
76%

DegenRx B.V. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 4, 2019
Series ADec 21, 2018

DegenRx B.V. Investors

Notable investors and investment history

DegenRx B.V. investors
InvestorRounds
Swanbridge CapitalSeries A
BOM Brabant VenturesSeries A
Health~HollandGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 4, 2019

    Received grant funding from Health~Holland.

  • Dec 21, 2018

    Raised Series A with BOM Brabant Ventures and Swanbridge Capital.

DegenRx B.V. Filings

Explore SEC and related filing metadata, where available.

DegenRx B.V. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about DegenRx B.V.'s valuation, stock price, and market status.

Is DegenRx B.V. a public or private company?

DegenRx B.V. is a private company.

What is the current stock price of DegenRx B.V.?

DegenRx B.V. is a private company with no public stock price. No recent secondary market data is available.

How much is DegenRx B.V. worth (valuation)?

Valuation information for DegenRx B.V. is not publicly available.

Can I buy DegenRx B.V. stock?

DegenRx B.V. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was DegenRx B.V.'s last funding round?

DegenRx B.V.'s most recent funding round was Grant on June 4, 2019.

Who are the main investors in DegenRx B.V.?

Key investors in DegenRx B.V. include Swanbridge Capital, BOM Brabant Ventures, Health~Holland.

Will DegenRx B.V. IPO soon?

No public IPO plans have been announced for DegenRx B.V..

How can I track DegenRx B.V. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DegenRx B.V.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTilburg
Year Founded2018
Last FundingJun 4, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?